Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-02-09
2011-12-20
Saoud, Christine J (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S389200, C424S130100, C424S133100
Reexamination Certificate
active
08080638
ABSTRACT:
The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the M×A promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
REFERENCES:
patent: 4362155 (1982-12-01), Skurkovich
patent: 4423147 (1983-12-01), Secher et al.
patent: 4474754 (1984-10-01), Shimizu et al.
patent: 4605394 (1986-08-01), Skurkovich
patent: 4824432 (1989-04-01), Skurkovich et al.
patent: 4902618 (1990-02-01), Berg et al.
patent: 4973556 (1990-11-01), Bove et al.
patent: 5055289 (1991-10-01), Frincke et al.
patent: 5503828 (1996-04-01), Testa et al.
patent: 5886153 (1999-03-01), Mogensen et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5889151 (1999-03-01), Mogensen et al.
patent: 5919453 (1999-07-01), Benoit et al.
patent: 6136309 (2000-10-01), Novick et al.
patent: 6333032 (2001-12-01), Skurkovich et al.
patent: 6458932 (2002-10-01), Novick et al.
patent: 6458934 (2002-10-01), Hong et al.
patent: 6475983 (2002-11-01), Eid et al.
patent: 6660523 (2003-12-01), Blom et al.
patent: 6713609 (2004-03-01), Chuntharapai et al.
patent: 6787634 (2004-09-01), Benoit et al.
patent: 7087726 (2006-08-01), Chuntharapai et al.
patent: 7179465 (2007-02-01), Benoit et al.
patent: 7544357 (2009-06-01), Banchereau et al.
patent: 2002/0160974 (2002-10-01), Banchereau et al.
patent: 2003/0018174 (2003-01-01), Kim et al.
patent: 2003/0021764 (2003-01-01), Maroun
patent: 2003/0147889 (2003-08-01), Tovey
patent: 2003/0166228 (2003-09-01), Chuntharapai et al.
patent: 2004/0067232 (2004-04-01), Banchereau et al.
patent: 2004/0067888 (2004-04-01), Tovey et al.
patent: 2004/0132139 (2004-07-01), Escary
patent: 2004/0170626 (2004-09-01), Schuurman et al.
patent: 2004/0191840 (2004-09-01), Benoit et al.
patent: 2005/0013799 (2005-01-01), Skurkovich et al.
patent: 2005/0013800 (2005-01-01), Skurkovich et al.
patent: 2005/0013813 (2005-01-01), Maroun
patent: 2007/0014724 (2007-01-01), Witte et al.
patent: 2007/0048311 (2007-03-01), Chuntharapai et al.
patent: 2009/0155286 (2009-06-01), Gilliet et al.
patent: 2009/0263474 (2009-10-01), Banchereau
patent: 2009/0324605 (2009-12-01), Witte et al.
patent: 0 325 471 (1989-07-01), None
patent: WO 93/04699 (1993-03-01), None
patent: WO 93/04699 (1993-03-01), None
patent: WO 98 06431 (1998-02-01), None
patent: WO 9828001 (1998-07-01), None
patent: WO 00 24417 (2000-05-01), None
patent: WO 01 36487 (2001-05-01), None
patent: WO 01 54721 (2001-08-01), None
patent: WO 02/066649 (2002-08-01), None
patent: WO 02/066649 (2002-08-01), None
patent: WO 02 067760 (2002-09-01), None
patent: WO 2004/003211 (2004-01-01), None
patent: WO 2004/003211 (2004-01-01), None
patent: WO 2004/094473 (2004-11-01), None
patent: WO 2004/094473 (2004-11-01), None
patent: WO 2005/059106 (2005-06-01), None
patent: WO 2005/059106 (2005-06-01), None
patent: WO 2006/037247 (2006-04-01), None
patent: WO 2006/037247 (2006-04-01), None
patent: WO 2006 037247 (2006-04-01), None
patent: WO 2006/086586 (2006-08-01), None
patent: WO 2008 021976 (2008-02-01), None
patent: WO 2009 135861 (2009-11-01), None
Vajdos et al. (2002), J. Mol. Biol., vol. 320, pp. 415-428.
Holm et al. (2007), Mol. immunol., vol. 44, pp. 1075-1084.
Chen et al. (1999), J. Mol. Biol., vol. 293, pp. 865-881.
Wu et al., (1999), J. Mol. Biol., vol. 294, pp. 151-162.
Rudikoff et al., (1982), Proc. Natl. Acad. Sci. USA ., vol. 79, pp. 1979-1983.
MacCallum et al., (1996), J. Mol. Biol., vol. 262, pp. 732-745.
Pascalis et al. , (2002), The Journal of imm., vol. 169, pp. 3076-3084.
Casset et al., (2003), BBRC, vol. 307, pp. 198-205.
Ngo et al. (1994), The Protein Folding Problem and tertiary Structure Prediction, pp. 492-495.
Wells. (1990), Biochemistry, vol. 26, No. 37, pp. 8509-8517.
U.S. Appl. No. 12/367,030, Banchereau et al.
International Preliminary Report on Patentability for International Application No. PCT/US07/75616; International Filing Date: Aug. 9, 2007; Date of Submission: Mar. 7, 2008; Date of Completion: May 19, 2009.
Pestka, Sidney et al.; “Interferon Standardization and Designations”;Journal of Interferon and Cytokine Research; 17 Supplement 1 Issue; pp. S9-S14; (1997).
Goeddel, David V. et al.; “The structure of eight distinct cloned human leukocyte interferon cDNAs”;Nature; vol. 290; pp. 20-26; Mar. 5, 1981.
Diaz, Manuel O. et al.; “Nomenclature of the Human Interferon Genesa”; Journal of Interferon Research; vol. 13, Issue 6; pp. 443-444; (1993).
Overall, Maree L. et al.; “Functional Analysis of Interferon-α Subtypes Using Monoclonal Antibodies to Interferon-α4α-Subtype Reactivity, Neutralisation of Biological Activities and Epitope Analysis”;Molecular Immunology; vol. 29, No. 3; pp. 391-399; (1992).
Chuntharapai, Anan et al.; “Characterization and Humanization of a Monoclonal Antibody that Neutralizes Human Leukocyte Interferon: A Candidate Therapeutic for IDDM and SLE”;Cytokine; vol. 15, No. 5; pp. 250-260; Sep. 7, 2001.
European Patent Office Communication pursuant to Article 94(3) EPC for Application No. 06734693.22402; Nov. 18, 2009.
Chang, K.C., et al. “Molecular and Functional Analysis of the Virus- and Interferon-Inducible Human MxA Promoter” Archives of Virology, 1991, pp. 1-15, vol. 117, Search Report.
Chuntharapai, A., et al., “Characterization and Humanization of a Monoclonal Antibody that Neutralizes Human Leukocyte Interferon: A Candidate Therapeutic for IDDM and SLE” Cytokine, Sep. 7, 2001, pp. 250-260, vol. 15, No. 5, Search Report.
Fray, M.D., et al., “Validation of anMx/Cat Reporter Gene Assay for the Quantification of Bovine Type-I Interferon” Journal of Immunological Methods, 2001, pp. 235-244, vol. 249, No. 1-2, Search Report.
Little, M. et al., “Of Mice and Men: Hybridoma and Recombinant Antibodies” Immunology Today, Aug. 1, 2000, pp. 364-370, vol. 21, No. 8, Search Report.
Overall, M.L., et al. “Functional Analysis of Interferon-α Subtypes using Monoclonal Antibodies to Interferon- α -4a-Subtype Reactivity, Neutralisation of Biological Activities and Epitope Analysis” Molecular Immunology, 1992, pp. 391-399, vol. 29, No. 3, Search Report.
Ronni, T., et al., “The Proximal Interferon-Stimulated Response Elements are Essential for Interferon Responsiveness: A Promoter Analysis of the Antiviral MxA Gene” Journal of Interferon and Cytokine Research, 1998 pp. 773-781, vol. 18, No. 9, Search Report.
Banchereau et al.; Office Action received from USPTO for co-pending U.S. Appl. No. 10/042,644, mailed Jul. 27, 2007.
Banchereau et al.; Office Action received from USPTO for co-pending U.S. Appl. No. 10/042,644, mailed Nov. 7, 2008.
Banchereau et al.; Office Action received from USPTO for co-pending U.S. Appl. No. 10/042,644, mailed Jun. 24, 2009.
Banchereau et al.; Office Action received from USPTO for co-pending U.S. Appl. No. 10/466,023, mailed Mar. 20, 2006.
Banchereau et al.; Office Action received from USPTO for co-pending U.S. Appl. No. 10/466,023, mailed Dec. 15, 2006.
Banchereau et al.; Office Action received from USPTO for co-pending U.S. Appl. No. 10/466,023, mailed Jun. 25, 2008.
Banchereau et al.; Notice of Allowance and Interview Summary received from USPTO for co-pending U.S. Appl. No. 1
Branchereau Jacques
Palucka Anna Karolina
Pascual Virginia
Prilliman Kiley
Baylor Research Institute
Sale Elaine T.
Saoud Christine J
Seharaseyon Jegatheesan
Thorne Leigh W.
LandOfFree
Anti-interferon alpha monoclonal antibodies and methods for use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-interferon alpha monoclonal antibodies and methods for use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-interferon alpha monoclonal antibodies and methods for use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254043